Abiraterone: Indication of considerable added benefit in certain patients

Advantages for men with metastatic hormone-refractory prostate cancer who are no longer eligible for docetaxel therapy

2012-01-09

(Press-News.org) Abiraterone (trade name: Zytiga®) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy.

IQWiG finds an indication of a considerable added benefit of abiraterone in patients who are not eligible for further treatment with docetaxel. In contrast, an added benefit is not proven in patients who can still be treated with docetaxel, as the dossier submitted by the drug manufacturer provides inadequate information for this group of patients.

Separate assessment for two groups of patients

In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed abiraterone in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.

The "best supportive care population" contains patients who are not eligible for further treatment with docetaxel. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as "best supportive care".

"Best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms (e.g. adequate pain therapy) and improve quality of life.

The "docetaxel-retherapy population" comprises patients who are still eligible for further treatment with docetaxel. The appropriate comparator therapy for this patient population is docetaxel in combination with prednisone or prednisolone.

Indication of increase in survival and delay in consequences of disease

One study (COU-AA-301), which considers patient-relevant outcomes and provides relevant data, was included in the assessment of added benefit in the "best supportive care population". This study compared treatment with abiraterone versus placebo, in each case combined with prednisone and "best supportive care".

IQWiG finds an indication of an added benefit in patients treated with abiraterone: the above study provides indications that abiraterone can prolong survival and delay consequences of prostate cancer, such as fractures or operations due to bone metastases. In addition, the "time to pain progression" was prolonged in study participants receiving abiraterone.

IQWiG classifies the extent of this added benefit as "considerable". The corresponding legal ordinance has specified three grades to determine the extent of added benefit: "minor", "considerable" and "major".

The study data presented on health-related quality of life assessments cannot be used; an added benefit of abiraterone is therefore not proven for this outcome.

The indications of advantages for abiraterone are not accompanied by proof of greater harm.

Added benefit in the docetaxel-retherapy population not proven

The manufacturer presented inadequate data for the "docetaxel-retherapy population". The required search in trial registries was missing in the dossier. Moreover, studies presented by the manufacturer, such as indirect comparisons and one-arm studies, cannot be used due to deficits in methods and content. An added benefit in this patient group is therefore not proven.

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.

### The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information (German version, http://www.gesundheitsinformation.de/prostatakrebs-welche-vor-oder-nachteile-hat-abirateron.804.de.html).

The G-BA website contains both general information (http://www.english.g-ba.de/special-topics/pharmaceuticals/benefitassessment/) on benefit assessments pursuant to §35a Social Code Book V and specific information on the assessment of abiraterone (German version, http://www.g-ba.de/informationen/nutzenbewertung/19/).

ELSE PRESS RELEASES FROM THIS DATE:

Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer

2012-01-09

TAMPA, Fla. (Jan. 6, 2012) – A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute. According to corresponding author Dung-Tsa Chen, Ph.D., associate member with the Moffitt Biostatistics program, non-small cell lung cancer (NSCLC) accounts for 80-90 percent of all lung cancers. ...

Hybrid silkworms spin stronger spider silk

2012-01-09

This week, research was published showing that silk produced by transgenically-engineered silkworms in the laboratory of Malcolm Fraser, Jr., professor of biological sciences at University of Notre Dame, exhibits the highly sought-after strength and elasticity of spider silk. This stronger silk could possibly be used to make sutures, artificial limbs and parachutes. The findings were published in the Proceedings of the National Academy of Sciences and highlighted for their breakthrough in the long search for silk with such mechanical properties. The manuscript was published ...

Mars rover to spend winter at 'Greeley Haven,' named for late ASU geologist Ronald Greeley

2012-01-09

TEMPE, Ariz. - NASA's Mars Exploration Rover Opportunity will spend the next few months during the coldest part of Martian winter at Greeley Haven, an outcrop of rock on Mars recently named informally to honor Ronald Greeley, Arizona State University Regents' professor of planetary geology, who died October 27, 2011. Long passionate about exploring the solar system and Mars in particular, Greeley was involved with many missions to the Red Planet, including Mariners 6, 7, and 9, Viking, Mars Pathfinder, Mars Global Surveyor, and the two Mars Exploration Rovers. He was ...

Experts offer pointers for optimizing radiation dose in pediatric CT

2012-01-09

An article in the January issue of the Journal of the American College of Radiology summarizes methods for radiation dose optimization in pediatric computed tomography (CT) scans. Approximately seven to eight million CT examinations are performed for various pediatric clinical indications per year in the United States. Justification of clinical indication is the most important aspect of reducing radiation dose with CT scanning. A substantial number of pediatric CT scans lack appropriate justification or can be replaced with other imaging modalities with lower or no ionizing ...

The nuclear, biological and climate threat - 2011 reviewed

2012-01-09

In this special issue of the Bulletin of the Atomic Scientists, published by SAGE, experts reflect on 2011 and highlight what to look out for in 2012 in the areas of nuclear energy, nuclear weapons, biosecurity, and climate change. Topics that have made the headlines during the previous 12 months, including the increased tension surrounding Iran's nuclear programme, the aftermath of the Fukushima incident, and the state of US policy on climate change, are analyzed in detail in this special issue. At the Doomsday Clock Symposium on January 9-10 in Washington, DC, the Bulletin's ...

Salk scientists map the frontiers of vision

2012-01-09

There's a 3-D world in our brains. It's a landscape that mimics the outside world, where the objects we see exist as collections of neural circuits and electrical impulses. Now, scientists at the Salk Institute for Biological Studies are using new tools they developed to chart that world, a key step in revolutionizing research into the neurological basis of vision. For the first time, the scientists have produced neuron-by-neuron maps of the regions of the mouse brain that process different kinds of visual information, laying the groundwork for decoding the circuitry ...

Tiny worm points to big promise

2012-01-09

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes. To do its job properly within the cell, a protein first must fold itself into the proper shape. If it doesn't, trouble can result. More than 300 diseases have at their root proteins that misfold, aggregate and eventually cause cellular dysfunction and death. The new Northwestern ...

Tobacco company misrepresented danger from cigarettes

2012-01-09

A new UCSF analysis of tobacco industry documents shows that Philip Morris USA manipulated data on the effects of additives in cigarettes, including menthol, obscuring actual toxicity levels and increasing the risk of heart, cancer and other diseases for smokers. Tobacco industry information can't be taken at face value, the researchers conclude. They say their work provides evidence that hundreds of additives, including menthol, should be eliminated from cigarettes on public health grounds. The article is published in PLoS Medicine http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001145 In ...

Majority groups support assimilation -- except when they're not majorities

2012-01-09

We generally think that views about how to integrate a diverse society depend on people's positions in that society—that is, whether they're in the racial, religious, or cultural majority or a member of a minority. In the U.S., "people tend to believe that blacks prefer pluralism and whites prefer assimilation," says University of Delaware psychologist Eric Hehman. Assimilation asks minorities—whether newly arrived or historically rooted—to drop their cultural identities and adopt the ways of the majority. Pluralism recognizes and even celebrates minority cultures, which ...

Better research is needed to understand why elders are happier

2012-01-09

Older people tend to be happier. But why? Some psychologists believe that cognitive processes are responsible—in particular, focusing on and remembering positive events and leaving behind negative ones; those processes, they think, help older people regulate their emotions, letting them view life in a sunnier light. "There is a lot of good theory about this age difference in happiness," says psychologist Derek M. Isaacowitz of Northeastern University, "but much of the research does not provide direct evidence" of the links between such phenomena and actual happiness. In ...